This study was performed because of accumulating evidence in pre-clinical studies that indicate that ASK1 inhibition might represent a novel therapeutic strategy for PAH since studies have shown that selonsertib oral administration to monocrotaline and Sugen/hypoxia rats reduced pulmonary arterial pressure and reduced RV hypertrophy. This evidence concerns the gene MAP3K5 and pulmonary arterial hypertension.